Nicole W Engen
Overview
Explore the profile of Nicole W Engen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
1194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bahr N, Skipper C, Huppler-Hullsiek K, Ssebambulidde K, Morawski B, Engen N, et al.
Clin Infect Dis
. 2022 Oct;
76(6):1080-1087.
PMID: 36303432
Background: Cryptococcal meningitis is a common cause of AIDS-related mortality. Although symptom recurrence after initial treatment is common, the etiology is often difficult to decipher. We sought to summarize characteristics,...
2.
Lofgren S, Okafor E, Colette A, Pastick K, Skipper C, Pullen M, et al.
Open Forum Infect Dis
. 2022 May;
8(11):ofab506.
PMID: 35548171
Background: During the coronavirus disease 2019 (COVID-19) pandemic, clinical trials necessitated rapid testing to be performed remotely. Dried blood spot (DBS) techniques have enabled remote HIV virologic testing globally, and...
3.
Chesdachai S, Engen N, Rhein J, Tugume L, Kandole T, Abassi M, et al.
Open Forum Infect Dis
. 2020 Dec;
7(12):ofaa530.
PMID: 33335936
Background: C-reactive protein (CRP) is an acute phase protein produced by the liver in response to systemic inflammation. CRP is a helpful surrogate biomarker used for following the progression and...
4.
Lofgren S, Nicol M, Bangdiwala A, Pastick K, Okafor E, Skipper C, et al.
Open Forum Infect Dis
. 2020 Nov;
7(11):ofaa500.
PMID: 33204764
Background: Use of hydroxychloroquine in hospitalized patients with coronavirus disease 2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns. Here, we report safety data from 3 outpatient randomized...
5.
Pullen M, Skipper C, Hullsiek K, Bangdiwala A, Pastick K, Okafor E, et al.
Open Forum Infect Dis
. 2020 Oct;
7(7):ofaa271.
PMID: 33117855
Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel pathogen causing the current worldwide coronavirus disease 2019 (COVID-19) pandemic. Due to insufficient diagnostic testing in the United States, there...
6.
Rajasingham R, Bangdiwala A, Nicol M, Skipper C, Pastick K, Axelrod M, et al.
Clin Infect Dis
. 2020 Oct;
72(11):e835-e843.
PMID: 33068425
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no known effective prophylaxis. We investigated whether hydroxychloroquine...
7.
Rajasingham R, Bangdiwala A, Nicol M, Skipper C, Pastick K, Axelrod M, et al.
medRxiv
. 2020 Sep;
PMID: 32995820
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging virus causing the ongoing Covid-19 pandemic with no known effective prophylaxis. We investigated whether hydroxychloroquine could prevent SARS...
8.
Skipper C, Atukunda M, Stadelman A, Engen N, Bangdiwala A, Hullsiek K, et al.
Antimicrob Agents Chemother
. 2020 Aug;
64(10).
PMID: 32747357
Amphotericin B deoxycholate (AMB) has substantial toxicities. A novel encochleated amphotericin B deoxycholate (cAMB) formulation has oral bioavailability, efficacy in an animal model, and minimal toxicity due to targeted drug...
9.
Lofgren S, Nicol M, Bangdiwala A, Pastick K, Okafor E, Skipper C, et al.
medRxiv
. 2020 Aug;
PMID: 32743591
Introduction: Use of hydroxychloroquine in hospitalized patients with COVID-19, especially in combination with azithromycin, has raised safety concerns. Here, we report safety data from three outpatient randomized clinical trials. Methods:...
10.
Skipper C, Pastick K, Engen N, Bangdiwala A, Abassi M, Lofgren S, et al.
Ann Intern Med
. 2020 Jul;
173(8):623-631.
PMID: 32673060
Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19). Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients. Design: Randomized, double-blind, placebo-controlled trial conducted...